Background. Splenomegaly in patients with cancer raises the suspicion
of tumor involvement. Splenic enlargement in the absence of splenic me
tastases, however, has been reported in patients treated with interleu
kin-2 (IL-2) immunotherapy. This study characterizes the change in spl
een size that occurred in 42 patients treated with IL-2 between 1989 a
nd 1993 for nonhematologic malignancies.Methods. Computed tomography (
CT) scans before and during immunotherapy were available for review on
all 42 patients and after immunotherapy on 16 of these patients. The
splenic index was measured for each CT by a single reader blinded to t
he time course of IL-2 therapy. Results. Mean splenic index increased
64.1% from 646 cm(3) (standard deviation [SD], 387) pre-IL-2 to 1059 c
m(3) (SD, 534) during therapy with IL-2 (P < 0.0001). The splenic inde
x remained elevated at 1112 cm(3) (SD, 633) after completion of IL-2 t
herapy. Conclusions. Splenomegaly, temporally associated with IL-2 the
rapy for nonhematologic malignancies, is likely to represent a sequela
of therapy and not tumor progression.